NCT07264699 Visually Guided TAP Block in Laparoscopic TAPP Hernia Repair
| NCT ID | NCT07264699 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Warmia and Mazury in Olsztyn |
| Condition | Inguinal Hernia Repair |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-04 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-12-04 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized clinical study aims to evaluate the effectiveness of the Transversus Abdominis Plane (TAP) block performed under direct laparoscopic vision in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique. The study will enroll 100 adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland. Participants will be randomly assigned to two equal groups. In the study group, a bilateral TAP block will be performed under direct vision using 20 ml of 0.25% bupivacaine on each side after establishing pneumoperitoneum. The control group will undergo the same surgical procedure without the TAP block. All patients will receive standardized anesthesia and postoperative pain management according to hospital protocol. Postoperative pain intensity will be assessed using the Visual Analogue Scale (VAS) at 0, 6, and 12 hours after surgery. Additional data, such as time to mobilization, use of rescue analgesics, and occurrence of postoperative complications (hematoma, swelling, subcutaneous emphysema, transient muscle weakness), will also be recorded. The primary goal of this study is to determine whether a laparoscopically guided TAP block can effectively reduce postoperative pain and improve recovery parameters following TAPP hernia repair. The results may help establish a simple, safe, and reproducible method of multimodal analgesia in minimally invasive inguinal hernia surgery.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years * Elective laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique * ASA physical status I-III * Ability to provide written informed consent * No contraindications to regional anesthesia or local anesthetic administration Exclusion Criteria: * Recurrent or strangulated inguinal hernia * Emergency surgery * Chronic pain syndromes or preoperative opioid use * Known allergy or hypersensitivity to local anesthetics (bupivacaine or similar) * Severe hepatic or renal impairment * Psychiatric disorders or inability to provide informed consent * Conversion to open surgery during the procedure * Technical difficulties preventing TAP block administration
Contact & Investigator
Marek Kowalczyk, PhD, MD
PRINCIPAL INVESTIGATOR
Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland
Frequently Asked Questions
Who can join the NCT07264699 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Inguinal Hernia Repair. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07264699 currently recruiting?
Yes, NCT07264699 is actively recruiting participants. Contact the research team at lukaszdysko@gmail.com for enrollment information.
Where is the NCT07264699 trial being conducted?
This trial is being conducted at Olsztyn, Poland.
Who is sponsoring the NCT07264699 clinical trial?
NCT07264699 is sponsored by University of Warmia and Mazury in Olsztyn. The principal investigator is Marek Kowalczyk, PhD, MD at Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland. The trial plans to enroll 100 participants.